Ruxolitinib Treatment Is Associated With Increased Incidence Of Infections And Higher Risk Of Hsv/Vzv Recurrence In Patients With Myeloproliferative Neoplasm (Mpn) Related Myelofibrosis (Mf)

Introduction: Ruxolitinib (RUX) is a JAK 1/2 inhibitor approved for the treatment of intermediate and high-risk primary or secondary MF. In addition to the intrinsic immune system modulation in MF patients, JAK inhibition exerts an immunosuppressive effect that may increase the risk of infections (Heine A et al., Blood, 2013). We aimed to investigate the association between treatment with RUX and infectious complications in a large monocentric cohort of MF patients.